Chemomab Therapeutics Ltd. and Scipher Medicine Corporation have entered into an all-stock merger agreement to create a Nasdaq-listed precision immunology company focused initially on nebokitug, a first-in-class anti-CCL24 antibody planned for a Phase 2 rheumatoid arthritis trial. The combined company is expected to operate as Scipher Medicine Corporation and trade under the ticker symbol SCIP,
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.
Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.
Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.
Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.
Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.
UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.
FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.